



University of Texas at El Paso

From the Selected Works of Laura Elena O'Dell

February 5, 2016

Insight into the potential.pdf

Laura Elena O'Dell, Ph.D.

Luis M Carcoba

Oscar V Torres

Joseph A Pipkin

Tiahna Ontiveros



Available at: https://works.bepress.com/laura_odell/62/

Insight into the Potential Factors That Promote Tobacco Use in Vulnerable Populations

Luis M. Carcoba¹ · Oscar V. Torres¹ · Joseph A. Pipkin¹ ·
Tiahna Ontiveros¹ · Laura E. O'Dell¹

Published online: 5 February 2016
© Springer International Publishing AG 2016

Abstract It is presently unclear why certain populations are more vulnerable to tobacco use and less responsive to smoking cessation interventions. This review considers the contribution of nicotine reward and withdrawal in populations that appear to be more susceptible to tobacco use. Our focus is on populations that have been modeled in rodents including, adolescents, females, and persons with metabolic disorders, such as diabetes. A common feature across these rodent models is heightened nicotine reward, suggesting that vulnerable populations may experience strong rewarding effects of nicotine that promote tobacco use. One distinguishing factor among these rodent models of at-risk populations is with regard to the magnitude of nicotine withdrawal, which is lower during adolescence. These groups also differ with regard to expression of the physical signs versus affective states produced by withdrawal, suggesting that these distinct facets of withdrawal differentially contribute to tobacco use in vulnerable populations. Thus, we may need to apply different diagnostic criteria and/or specialized treatments that target the unique factors that promote tobacco use in different vulnerable populations.

Keywords Adolescence · Diabetes · Females · Nicotine · Smoking · Withdrawal

This article is part of the Topical Collection on *Tobacco*

Drs. Luis M. Carcoba and Oscar V. Torres contributed equally to the development of this work.

✉ Laura E. O'Dell
lodell@utep.edu

¹ Department of Psychology, The University of Texas at El Paso, 500 W. University Avenue, El Paso, TX 79968, USA

Introduction

Epidemiological evidence has suggested that high rates of tobacco use contribute to health disparities in vulnerable populations. However, it is unclear why certain groups are more susceptible to using tobacco and are less likely to respond to cessation approaches. This review considers the different factors that may promote tobacco use in certain at-risk populations. The addictive nature of tobacco has been largely attributed to nicotine, a major alkaloid component of tobacco [1, 2]. Following chronic tobacco use, abstinence from this drug elicits a withdrawal syndrome that is believed to drive continued use and relapse behavior. This review considers clinical and pre-clinical studies that have compared nicotine reward and withdrawal in adolescents, females, and individuals with diabetes. Our assessment of the literature suggests that strong rewarding effects of nicotine promote tobacco use among vulnerable populations. Also, there are group differences with regard to nicotine withdrawal that may contribute to enhanced tobacco use in certain groups. This review also addresses the neurochemical systems that modulate group differences in nicotine withdrawal. Continued research on the biological mechanisms that promote tobacco use is important towards developing specialized medications that will target the unique factors that promote tobacco use in vulnerable populations.

Nicotine Reward and Withdrawal

Tobacco use is motivated by at least two processes involving the positive rewarding effects of nicotine and avoiding the negative consequences of withdrawal from this drug. Initially, tobacco use is largely motivated by the positive rewarding effects of nicotine that sustain continued use. Nicotine also possesses short-term aversive effects that may

limit initial use or discourage future experimentation with tobacco products. In rodents, the most common models used to study the rewarding effects of nicotine involve intravenous self-administration (IVSA) and place preference procedures involving classical conditioning between the subjective effects of nicotine and external environmental cues [3]. In rodents, nicotine produces rewarding (conditioned place preference; CPP) or aversive (conditioned place aversion; CPA) effects depending on the dose of nicotine that is used.

Following chronic tobacco use, withdrawal from nicotine produces a milieu of withdrawal symptoms including physical signs, negative affective states and cognitive deficits (see Table 1; [4]). Growing evidence suggests that the physical signs of withdrawal are mechanistically distinct from negative affective states. Early studies addressing this issue revealed that the physical signs of withdrawal are mediated via central and peripheral nicotinic acetylcholine receptors (nAChRs), whereas affective states are modulated via central nAChRs [5, 6]. A recent review summarizing the role of various nAChR subunits revealed that $\alpha 2$, $\alpha 3$, $\alpha 5$, $\alpha 7$, and $\beta 4$ modulate physical signs, whereas $\alpha 6$ and $\beta 2$ modulate affective states produced by nicotine withdrawal [7]. Also, a recent study revealed that the physical signs of withdrawal were not correlated with high levels of anxiety or nicotine intake observed during abstinence from extended access to nicotine IVSA [8]. Together, these studies suggest that the physical

versus negative affective states produced by withdrawal are modulated via distinct mechanisms. By extension, one might also predict that there are unique factors that promote tobacco use across different at-risk populations such as adolescents, females, and persons with diabetes.

Tobacco Use in Vulnerable Populations

Adolescence There is a myriad of external factors that promote the initiation of tobacco use during adolescence, such as enhanced risk-taking, peer pressure, and concerns about weight gain [9–11]. To our knowledge, the rewarding effects of nicotine have not been directly compared in adolescent and adult tobacco users. However, it is well established that adults who initiate smoking during adolescence are more likely to continue smoking into adulthood as compared to adults that initiate smoking later in life [12, 13]. Pre-clinical studies have shown that nicotine reward is enhanced during the adolescent period of development (post-natal days 28–45; [14]). For example, adolescent rodents display greater nicotine CPP as compared to adults across a wide range of experimental protocols, nicotine doses, and routes of administration [15–22]. Studies using IV and oral SA procedures have also shown that nicotine intake is higher in adolescent versus adult rats [23–28] and mice [29]. High doses of

Table 1 Physical and affective states produced by nicotine withdrawal

	Rodents	Humans
Physical signs	Gasps	Bradycardia
	Abdominal constrictions (writhes)	Gastrointestinal discomfort
	Facial fasciculations	Increased appetite
	Eye blinks and ptosis	
	Teeth chatters	
	Escape attempts and rearing	
	Head and body shakes	
	Yawns and paw licks	
	Decreased activity	
	Hyperalgesia	Increased pain sensitivity
Affective states	Negative affective states:	Craving
	-Place aversion	Depressed mood
	-Taste aversion	Dysphoria
	-Lower brain stimulation reward thresholds	
	Anxiety-like behavior:	Stress and anxiety
	Increases in:	Irritability
	-Closed arm time (elevated plus maze)	
	-Corner time (open field)	
	-Latency to enter dark side (light dark transfer)	
	-Latency to bury (marble burying)	
Cognitive deficits	Memory and attention deficits	Difficulty concentrating

For a recent and comprehensive review of the physical and affective states produced by withdrawal in rodents and humans, the reader is referred to Hall et al. [4]

nicotine also produce aversive effects that are lower in adolescent versus adult rats [18, 30].

With regard to withdrawal, clinical studies have revealed that young smokers exhibit milder symptoms of withdrawal during abstinence from smoking [31], and they are less responsive to cessation approaches that alleviate withdrawal [32–34]. However, it is also acknowledged that young smokers display robust cue-elicited craving despite occasional cigarette use [35]. Pre-clinical studies have shown that the physical signs of nicotine withdrawal are generally lower in adolescent versus adult rats [36] and mice [16]. Also, the negative affective states elicited during nicotine withdrawal are lower in adolescent versus adult rats in intracranial self-stimulation [36] and CPA [30, 37] procedures. It should be noted, however, that nicotine withdrawal produces an increase in anxiety-like behavior that is similar in adolescent and adult mice [38]. Nicotine withdrawal also produces cognitive impairments that are greater in adolescent rats, suggesting that improved cognitive abilities may amplify tobacco use during adolescence [39]. In summary, these studies suggest that the rewarding effects of nicotine are greater, but the behavioral effects of nicotine withdrawal are lower during the adolescent period of development.

Females The rewarding effects of nicotine appear to be greater in females versus males. For example, self-reports of positive mood effects are higher in women versus men smokers [40]. Additionally, female smokers display greater responding for smoking-related cues and lower quit rates as compared to men [41, 42]. However, the rates of current smoking have been reported to be slightly higher in males (18.8 %) than females (14.8 %) according to the 2014 Morbidity and Mortality Weekly Report of the Centers for Disease Control and Prevention. Pre-clinical studies have shown that females display a more robust CPP produced by nicotine than male rats [21] and mice [38]. Also, CPP is produced following a single drug pairing in female, but not male, rats [43]. Female rats also display higher levels of nicotine IVSA following presentation of conditioned stimuli as compared to males [44, 45]. However, another study found that female and male rats display similar levels of nicotine intake and reinstatement of extinguished nicotine-seeking behavior [46]. The authors of the latter report suggest that their lack of sex differences may be related to their use of low reinforcement requirements.

With regard to withdrawal, clinical studies have shown that women report that the primary reason for smoking and relapse behavior is to reduce anxiety and avoid stress [47, 48]. Indeed, women report greater levels of anxiety, depression, and stress [49–51] and they display higher levels of cortisol (a biological marker of stress in humans) during smoking abstinence as compared to men [52]. Pre-clinical studies have shown that the physical signs of nicotine

withdrawal are similar in female and male rats; however, CPA produced by withdrawal is larger in female versus male mice [16, 38] and rats [53••]. Female rats also display an increase in anxiety-like behavior and plasma corticosterone levels that is larger than males [54–56]. These studies suggest that nicotine withdrawal induces similar physical signs in females and males; however, the negative affective states induced by withdrawal is larger in females. The latter effect appears to be modulated via ovarian hormones, as ovariectomized (OVX) females do not display anxiety-like behavior during withdrawal [57]. In summary, these studies suggest that both nicotine reward and withdrawal are greater in females as compared to males.

Diabetes Persons with metabolic disorders, such as diabetes, appear to be more prone to using tobacco. Much of the clinical work in this area has focused on patients with type 1 diabetes, which is a condition that produces little to no release of insulin from the pancreas. Smoking rates in adolescents with type 1 diabetes are higher than healthy controls (47 versus 38 %; [58]). Also, persons with type 1 diabetes report higher rates of current smoking (12.3 %) as compared to non-diabetic subjects (8.6 %; [59]). A recent examination of cigarette smoking trends from 2001 to 2010 revealed that smoking rates are similar in persons with and without diabetes [60]. However, the latter survey also revealed that the decline in smoking rates over this period is lower in persons with diabetes, indicating a sustained use of tobacco in persons with diabetes. Pre-clinical studies have employed two common models of diabetes involving streptozotocin (STZ) administration or a chronic high-fat diet (HFD) regimen [61]. STZ is a drug that is taken up via glucose (type 2) transporters that are concentrated on the insulin-producing beta cells of the pancreas. STZ is toxic to these cells and, as a result, produces a decrease in insulin (hypoinsulinemia) and a concomitant increase in blood glucose (hyperglycemia). The HFD model of diabetes produces insulin resistance and hyperglycemia following chronic exposure to a HFD regimen. Pre-clinical studies have revealed that STZ-treated rats display higher levels of nicotine IVSA as compared to healthy controls [62]. A subsequent study revealed that insulin resistance, produced by HFD regimen, potentiates CPP produced by nicotine [63]. This suggests that insulin resistance enhances nicotine reward via a disruption of insulin signaling. However, another report revealed that mice placed on a HFD regimen do not display nicotine CPP [64]. The discrepancy in these reports may be related to metabolic differences between rats and mice and/or different doses of nicotine and routes of administration.

With regard to withdrawal, persons with diabetes display higher rates of depression and anxiety during abstinence as compared to non-diabetic smokers [65]. Diabetic persons that smoke also display higher levels of stress, negative affect, and depression as compared to non-smokers [66, 67]. To our

knowledge, pre-clinical studies have not compared nicotine withdrawal in rodent models of diabetes. However, unpublished observations in our laboratory have revealed that STZ-treated rats display more physical signs and a larger magnitude of CPA and anxiety-like behavior produced by withdrawal as compared to controls. These studies suggest that both nicotine reward and withdrawal are greater in hypoinsulinemic rats as compared to controls.

Summary of Behavioral Studies Figure 1 depicts the factors that promote tobacco use in adolescents, females, and subjects with diabetes. A common factor that appears to promote tobacco use across all groups is the strong rewarding effects of nicotine that are unopposed by the direct aversive effects of this drug. There are group differences, however, with regard to the contribution of withdrawal. In adolescents, both the physical signs and negative affective states produced by withdrawal are lower than adults. Thus, it has been suggested that the strong rewarding effect of nicotine is a major contributing factor to enhanced tobacco use during adolescence [68–71]. In females, nicotine withdrawal produces an intense anxiety-like behavior but similar physical signs as compared to males. Hence, both the strong rewarding effect of nicotine and intense anxiety produced by withdrawal promote tobacco use in females [53•, 57, 72, 73]. In diabetes, both the physical signs and affective states produced by withdrawal are heightened as compared to controls. This is noted as a larger arrow

that consists of both facets of withdrawal. As a result, it has been suggested that both the strong rewarding effect of nicotine and intense physical signs and affective states produced by withdrawal promote tobacco use in subjects with diabetes [74–76]. This review is intended to highlight the primary factors that drive tobacco use in these vulnerable groups, and future studies are needed to cross compare which populations and unique factors are most critical towards promoting tobacco use in groups that are most at risk for tobacco use. Given the different contribution of these factors, one might predict that the underlying mechanisms that modulate these facets of withdrawal are distinct.

Mechanisms of Nicotine Withdrawal in Vulnerable Populations

The neurochemical systems discussed here focus on the mesolimbic pathway because this system has been shown to play a central role in modulating nicotine reward and withdrawal, and previous work comparing nicotine use in vulnerable populations has largely focused on this pathway. The mesolimbic pathway has dopaminergic fibers originating in the ventral tegmental area (VTA) that project to a series of forebrain structures within the extended amygdala, including the central nucleus of the amygdala, bed nucleus of the stria terminalis (BNST), and the shell of the nucleus accumbens




Fig. 1 The arrows depict the downward trajectory of nicotine dependence from the initial rewarding effects of this drug to the emergence of a withdrawal syndrome during abstinence. The contribution of nicotine reward and withdrawal is denoted in adolescents, females, and persons with diabetes. The size of the arrow reflects the relative contribution of these factors relative to their respective

controls (i.e., adult males that use tobacco but are otherwise healthy). Across all groups, a common factor that contributes to tobacco use is the strong rewarding effects of nicotine. However, there are significant group differences with regard to the magnitude of nicotine withdrawal and the degree to which the physical signs versus affective states contribute to tobacco use in these at-risk populations

(NAcc; [77]). Much work has demonstrated that nicotine enhances dopamine transmission in the NAcc, via excitatory glutamate input from the prefrontal cortex and inhibitory gamma-aminobutyric acid (GABA) innervation from local interneurons [78, 79]. While the NAcc is a key structure involved in nicotine reward, withdrawal from this drug produces a decrease in NAcc dopamine levels that is believed to serve as a biomarker of withdrawal from drugs of abuse [80–82]. The decrease in NAcc dopamine levels produced by nicotine withdrawal appears to be modulated via an increase in GABA and a decrease in glutamate levels in the VTA [27]. Given the importance of the NAcc in modulating nicotine withdrawal, the following sections focus on the changes in this structure that might explain group differences produced by nicotine withdrawal.

Adolescence Initial studies comparing age differences produced by nicotine withdrawal revealed that adolescents display a smaller decrease in NAcc dopamine levels than adults [27]. Subsequent studies revealed that this neurochemical resistance is modulated via enhanced glutamate and reduced GABA release in the VTA [83]. Adolescent rats were also resistant to the decreases in NAcc dopamine levels produced by administration of a kappa agonist in nicotine-dependent rats [84]. Subsequent studies revealed that adolescent and adult rats display similar increases in ACh levels [85] and stress-associated genes [57] in the NAcc during nicotine withdrawal. Taken together, these studies suggest that age differences produced by nicotine withdrawal are modulated via NAcc dopamine systems.

Females The NAcc appears to also modulate sex differences in nicotine withdrawal. Initial studies comparing sex differences produced by nicotine withdrawal revealed that adult females display an increase in the expression of CRF mRNA in the NAcc that is larger than males [56]. CRF is thought to undergo a dynamic shift from facilitating hedonic states to promoting aversive states produced by chronic stress. This is based on the finding that intra-NAcc infusions of CRF produce CPP and an increase in local dopamine levels in naïve rats [86]. However, intra-NAcc CRF administration produces CPA and a reduction in dopamine levels in chronically stressed rats. Recently, we postulated that nicotine withdrawal induces a larger increase in CRF and, as a result, a larger decrease in dopamine in the NAcc in females as compared to males [57]. This hypothesis is based on our finding that adult females display a larger increase in dopamine (D1) receptor mRNA levels in the NAcc than males [57]. The latter result is believed to serve as indirect evidence that dopamine levels are lower in the NAcc of females versus males during withdrawal. In our mechanistic hypothesis, we also postulated that the decrease in NAcc dopamine is modulated via a CRF/GABA interaction. This is based on the finding that activation

of CRF-R1 receptors in the NAcc increases GABA and decreases dopamine levels in this region [87]. Thus, we postulate that females display heightened CRF release and activation of CRF-R1 receptors that increases GABA and decreases dopamine levels in the NAcc. In support of our working hypothesis, unpublished observations have revealed that nicotine withdrawal produces an increase in NAcc GABA levels that are higher in female versus male rats. Work in other laboratories has also shown that females display overactivation of CRF stress systems. For example, Bangasser et al. [88] demonstrated that female rats display higher levels of CRF and a larger ratio of CRF-1 receptor coupling to G-proteins as compared to males. Female rats also display lower levels of beta-arrestin2, a protein that modulates CRF-R1 receptor internalization [53•, 89]. Taken together, it is suggested that the ability of CRF to modulate NAcc dopamine via GABA is disproportionately greater in females as compared to males.

Diabetes To our knowledge, no one has compared the neurochemical mechanisms of nicotine withdrawal in rodent models of diabetes. Previous studies have shown that STZ-treated rats display a profound suppression of dopamine release and D1 receptors in the NAcc [62]. Also, STZ-treated rats display a suppression of dopamine release in the dorsal striatum [90–94]. Based on the finding that STZ-treated rats display a general suppression of dopamine transmission, one might predict that hypoinsulinemic rats would display a larger decrease in NAcc dopamine levels during nicotine withdrawal. Future studies are needed to examine this important question, especially given that diabetic patients may self-medicate their deficits in dopamine with substances, such as nicotine.

Summary To date, our work has focused on the underlying factors that play a central role in promoting tobacco use in populations that are at greater risk for using tobacco. Although it is not possible at this time to provide a unifying hypothesis to explain why certain populations are more vulnerable to tobacco use, we have taken important steps towards understanding the unique factors that promote tobacco use in certain groups. Namely, in adolescents, our work suggests that a heightened regulation of dopamine in the NAcc promotes the rewarding effects of nicotine and protects from the decreases in dopamine produced by withdrawal. In females, the strong rewarding effects of nicotine and intense stress produced by withdrawal are modulated via enhanced CRF systems that regulate dopamine release in the NAcc. In diabetic rodent subjects, hypoinsulinemia produces a profound suppression of dopamine systems in the NAcc that may lead to profound reductions in dopamine during withdrawal. Future studies are needed to more fully understand the complex

network of brain systems that promote tobacco use in vulnerable populations.

Alternative Systems That May Modulate Group Differences in Withdrawal

Recent evidence suggests that nicotine withdrawal is also modulated via the habenula-interpeduncular (Hb-IPN) pathway [95•, 96, 97]. Microinjections of a nAChR antagonist in the habenula or IPN elicit physical signs of withdrawal in nicotine-dependent mice [98•]. However, the latter effect was not observed following injections in other regions, such as the VTA, cortex, or hippocampus. Also, intra-IPN infusions of a glutamate antagonist facilitate marble burying produced by nicotine withdrawal, and this effect is reversed following administration of a CRF-R1 antagonist [98•].

Recently, it has been suggested that the Hb-IPN and mesolimbic pathways play a distinct role in modulating the physical versus affective components of withdrawal [99•]. Indeed, there is a high density of $\alpha 5$ and $\beta 4$ nAChR subunits in the Hb-IPN pathway, and mice lacking these subunits display fewer physical signs and heightened hyperalgesia produced by withdrawal [97, 100]. On the other hand, there is a higher density of $\alpha 6$ and $\beta 2$ nAChR in the VTA as compared to the habenula or IPN, and mice lacking these subunits display reduced anxiety-like behavior but no differences in physical signs produced by nicotine withdrawal [100]. Furthermore, intracerebroventricular injections of an $\alpha 6$ antagonist attenuated CPA and anxiety-like behavior but had no effect on the physical signs of nicotine withdrawal in wild-type mice [101].

With regard to vulnerable populations, we have observed that the physical signs and affective states produced by withdrawal are separable. Namely, adolescents display fewer physical signs but similar affective states as compared to adults experiencing nicotine withdrawal [20, 36]. Also, female adult rats display greater negative affective states but similar physical signs of withdrawal than males [21]. These data suggest that there are group differences in the physical versus affective states produced by withdrawal. These group differences are likely modulated within distinct circuits in the brain, such as the mesolimbic and/or Hb-IPN pathway. Indeed, the habenula is a sexually dimorphic nucleus with regard to sexual behavior and the distribution of androgen and estrogen receptor mRNA in this region [102, 103]. Future research is needed to examine the unique contribution of the mesolimbic and Hb-IPN pathways in promoting tobacco use in different vulnerable populations. There are also connections between the mesolimbic and

Hb-IPN pathways that may modulate different aspects of nicotine withdrawal. Indeed, the IPN receives heavy glutamatergic input from the medial habenula and dense CRF innervation from the VTA [98•, 104•]. This suggests that there is likely cross communication between the mesolimbic and Hb-IPN pathways that form a larger brain construct that modulates nicotine withdrawal.

Conclusion and Clinical Implications

The information provided here offers some clinical implications to consider. First, we may need to focus our efforts of providing a better understanding of the mechanisms that modulate the unique factors that promote tobacco use in at-risk groups. This will help guide the development of more specialized and effective treatments for smoking cessation in vulnerable populations. Second, a common factor that promotes tobacco use in vulnerable populations is the strong rewarding effect of nicotine. Thus, it is important to educate populations that may be more susceptible to initiating tobacco use, especially given that marketing strategies target certain groups, such as young females that are particularly susceptible to tobacco use. Third, our findings suggest that group differences in withdrawal may alter our approach to smoking cessation in different groups. In adolescents, we may need to apply different diagnostic criteria or smoking cessation medications in young persons that may not experience strong nicotine withdrawal and/or deficits in dopamine. In females, our results suggest that the most effective smoking cessation treatments may need to target stress that plays an important role in tobacco use and relapse behavior in women. As a whole, our work implies that health care professionals should assess the demographic and health background of their patients in order to deliver more specialized treatments that might be more effective in certain vulnerable populations.

Acknowledgments The authors would like to thank Bryan Cruz, Rodolfo Flores, and Kevin Uribe for their helpful comments in the preparation of this review paper. The authors also appreciate the support that was provided from The National Institute on Drug Abuse (R01-DA021274, R15-DA040130, R24-DA029989, and R25-DA033613) and the National Institute of Minority Health Disparities (G12MD007592) as part of the UTEP Border Biomedical Research Center.

Compliance with Ethical Standards

Conflict of Interest Luis M. Carcoba, Oscar V. Torres, Joseph A. Pipkin, Tiahna Ontiveros, and Laura E. O'Dell declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Goodwin AK, Hiranita T, Paule MG. The reinforcing effects of nicotine in humans and nonhuman primates: a review of intravenous self-administration evidence and future directions for research. *Nicotine Tob Res*. 2015;17(11):1297–310. doi:10.1093/ntr/ntv002.
2. Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. *Psychopharmacol (Berl)*. 1995;117(1):2–10.
3. O'Dell LE, Khroyan TV. Rodent models of nicotine reward: what do they tell us about tobacco abuse in humans? *Pharmacol Biochem Behav*. 2009;91(4):481–8. doi:10.1016/j.pbb.2008.12.011.
4. Hall FS, Der-Avakian A, Gould TJ, Markou A, Shoaib M, Young JW. Negative affective states and cognitive impairments in nicotine dependence. *Neurosci Biobehav Rev*. 2015. doi:10.1016/j.neubiorev.2015.06.004.
5. Watkins SS, Stinus L, Koob GF, Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. *J Pharmacol Exp Ther*. 2000;292(3):1053–64.
6. De Biasi M, Dani JA. Reward, addiction, withdrawal to nicotine. *Annu Rev Neurosci*. 2011;34:105–30. doi:10.1146/annurev-neuro-061010-113734.
7. Jackson KJ, Muldoon PP, De Biasi M, Damaj MI. New mechanisms and perspectives in nicotine withdrawal. *Neuropharmacology*. 2015;96(Pt B):223–34. doi:10.1016/j.neuropharm.2014.11.009. **This article provides a comprehensive review on the neurobiological mechanisms of nicotine withdrawal and the neuroadaptive mechanisms influencing nicotine withdrawal, including sex, age and genetic factors.**
8. Cohen A, Soleiman MT, Talia R, Koob GF, George O, Mandym CD. Extended access nicotine self-administration with periodic deprivation increases immature neurons in the hippocampus. *Psychopharmacol (Berl)*. 2015;232(2):453–63. doi:10.1007/s00213-014-3685-0.
9. Silveri MM, Tzilos GK, Pimentel PJ, Yurgelun-Todd DA. Trajectories of adolescent emotional and cognitive development: effects of sex and risk for drug use. *Ann N Y Acad Sci*. 2004;1021:363–70.
10. Hussaini AE, Nicholson LM, Shera D, Stettler N, Kinsman S. Adolescent obesity as a risk factor for high-level nicotine addiction in young women. *J Adolesc Health*. 2011;49(5):511–7. doi:10.1016/j.jadohealth.2011.04.001.
11. Laviola G, Adriani W, Terranova ML, Gerra G. Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. *Neurosci Biobehav Rev*. 1999;23(7):993–1010.
12. Eissenberg T, Balster RL. Initial tobacco use episodes in children and adolescents: current knowledge, future directions. *Drug Alcohol Depend*. 2000;59 Suppl 1:S41–60.
13. Pomerleau CS, Pomerleau OF, Namenek RJ, Marks JL. Initial exposure to nicotine in college-age women smokers and never-smokers: a replication and extension. *J Addict Dis*. 1999;18(3):13–9.
14. Spear LP. The adolescent brain and age-related behavioral manifestations. *Neurosci Biobehav Rev*. 2000;24(4):417–63.
15. Belluzzi JD, Lee AG, Oliff HS, Leslie FM. Age-dependent effects of nicotine on locomotor activity and conditioned place preference in rats. *Psychopharmacol (Berl)*. 2004;174(3):389–95.
16. Kota D, Martin BR, Robinson SE, Damaj MI. Nicotine dependence and reward differ between adolescent and adult male mice. *J Pharmacol Exp Ther*. 2007;322(1):399–407.
17. Lenoir M, Starosciak AK, Ledon J, Booth C, Zakharova E, Wade D, et al. Sex differences in conditioned nicotine reward are age-specific. *Pharmacol Biochem Behav*. 2015;132:56–62. doi:10.1016/j.pbb.2015.02.019.
18. Shram MJ, Funk D, Li Z, Lê AD. Periadolescent and adult rats respond differently in tests measuring the rewarding and aversive effects of nicotine. *Psychopharmacol (Berl)*. 2006;186(2):201–8.
19. Shram MJ, Lê AD. Adolescent male Wistar rats are more responsive than adult rats to the conditioned rewarding effects of intravenously administered nicotine in the place conditioning procedure. *Behav Brain Res*. 2010;206(2):240–4. doi:10.1016/j.bbr.2009.09.018.
20. Torres OV, Tejeda HA, Natividad LA, O'Dell LE. Enhanced vulnerability to the rewarding effects of nicotine during the adolescent period of development. *Pharmacol Biochem Behav*. 2008;90(4):658–63. doi:10.1016/j.pbb.2008.05.009.
21. Torres OV, Natividad LA, Tejeda HA, Van Weelden SA, O'Dell LE. Female rats display dose-dependent differences to the rewarding and aversive effects of nicotine in an age-, hormone-, and sex-dependent manner. *Psychopharmacol (Berl)*. 2009;206(2):303–12. doi:10.1007/s00213-009-1607-3.
22. Vastola BJ, Douglas LA, Varlinskaya EI, Spear LP. Nicotine-induced conditioned place preference in adolescent and adult rats. *Physiol Behav*. 2002;77(1):107–14.
23. Chen H, Matta SG, Sharp BM. Acquisition of nicotine self-administration in adolescent rats given prolonged access to the drug. *Neuropsychopharmacology*. 2007;32(3):700–9.
24. Levin ED, Rezvani AH, Montoya D, Rose JE, Swartzwelder HS. Adolescent-onset nicotine self-administration modeled in female rats. *Psychopharmacol (Berl)*. 2003;169(2):141–9.
25. Levin ED, Lawrence SS, Petro A, Horton K, Rezvani AH, Seidler FJ, et al. Adolescent vs. adult-onset nicotine self-administration in male rats: duration of effect and differential nicotinic receptor correlates. *Neurotoxicol Teratol*. 2007;29(4):458–65.
26. Levin ED, Slade S, Wells C, Cauley M, Petro A, Vendittelli A, et al. Threshold of adulthood for the onset of nicotine self-administration in male and female rats. *Behav Brain Res*. 2011;225(2):473–81. doi:10.1016/j.bbr.2011.08.005.
27. Natividad LA, Tejeda HA, Torres OV, O'Dell LE. Nicotine withdrawal produces a decrease in extracellular levels of dopamine in the nucleus accumbens that is lower in adolescent versus adult male rats. *Synapse*. 2010;64(2):136–45. doi:10.1002/syn.20713.
28. Nesil T, Kanit L, Collins AC, Pogun S. Individual differences in oral nicotine intake in rats. *Neuropharmacology*. 2011;61(1–2):189–201. doi:10.1016/j.neuropharm.2011.03.027.
29. Adriani W, Macri S, Pacifici R, Laviola G. Peculiar vulnerability to nicotine oral self-administration in mice during early adolescence. *Neuropsychopharmacology*. 2002;27(2):212–24.
30. O'Dell LE, Torres OV, Natividad LA, Tejeda HA. Adolescent nicotine exposure produces less affective measures of withdrawal relative to adult nicotine exposure in male rats. *Neurotoxicol Teratol*. 2007;29(1):17–22.
31. Smith AE, Cavallo DA, Dahl T, Wu R, George TP, Krishnan-Sarin S. Effects of acute tobacco abstinence in adolescent smokers compared with nonsmokers. *J Adolesc Health*. 2008;43(1):46–54. doi:10.1016/j.jadohealth.2007.12.004.
32. Bailey SR, Crew EE, Riske EC, Ammerman S, Robinson TN, Killen JD. Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents. *Paediatr Drugs*. 2012;14(2):91–108. doi:10.2165/11594370-000000000-00000.

33. Grimshaw GM, Stanton A. Tobacco cessation interventions for young people. *Cochrane Database Syst Rev*. 2006;4, CD003289.
34. Hanson K, Allen S, Jensen S, Hatsukami D. Treatment of adolescent smokers with the nicotine patch. *Nicotine Tob Res*. 2003;5(4):515–26.
35. Carpenter MJ, Saladin ME, Larowe SD, McClure EA, Simonian S, Upadhyaya HP, et al. Craving, cue reactivity, and stimulus control among early-stage young smokers: effects of smoking intensity and gender. *Nicotine Tob Res*. 2014;16(2):208–15. doi:10.1093/ntr/ntt147.
36. O'Dell LE, Bruijnzeel AW, Smith RT, Parsons LH, Merves ML, Goldberger BA, et al. Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction. *Psychopharmacol (Berl)*. 2006;186(4):612–9.
37. Shram MJ, Siu EC, Li Z, Tyndale RF, Lê AD. Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. *Psychopharmacol (Berl)*. 2008;198(2):181–90. doi:10.1007/s00213-008-1115-x.
38. Kota D, Martin BR, Damaj MI. Age-dependent differences in nicotine reward and withdrawal in female mice. *Psychopharmacol (Berl)*. 2008;198(2):201–10. doi:10.1007/s00213-008-1117-8.
39. Wilmouth CE, Spear LP. Withdrawal from chronic nicotine in adolescent and adult rats. *Pharmacol Biochem Behav*. 2006;85(3):648–57.
40. Perkins KA, Doyle T, Ciccocioppo M, Conklin C, Sayette M, Caggiula A. Sex differences in the influence of nicotine dose instructions on the reinforcing and self-reported rewarding effects of smoking. *Psychopharmacol (Berl)*. 2006;184(3–4):600–7.
41. Perkins KA, Gerlach D, Vender J, Grobe J, Meeker J, Hutchison S. Sex differences in the subjective and reinforcing effects of visual and olfactory cigarette smoke stimuli. *Nicotine Tob Res*. 2001;3(2):141–50.
42. Zilberman M, Tavares H, El-Guebaly N. Gender similarities and differences: the prevalence and course of alcohol- and other substance-related disorders. *J Addict Dis*. 2003;22(4):61–74.
43. Edwards AW, Konz N, Hirsch Z, Weedon J, Dow-Edwards DL. Single trial nicotine conditioned place preference in pre-adolescent male and female rats. *Pharmacol Biochem Behav*. 2014;125:1–7. doi:10.1016/j.pbb.2014.07.016.
44. Chaudhri N, Caggiula AR, Donny EC, Booth S, Gharib MA, Craven LA, et al. Sex differences in the contribution of nicotine and nonpharmacological stimuli to nicotine self-administration in rats. *Psychopharmacol (Berl)*. 2005;180(2):258–66.
45. Donny EC, Caggiula AR, Rowell PP, Gharib MA, Maldovan V, Booth S, et al. Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding. *Psychopharmacol (Berl)*. 2000;151(4):392–405.
46. Feltenstein MW, Ghee SM, See RE. Nicotine self-administration and reinstatement of nicotine-seeking in male and female rats. *Drug Alcohol Depend*. 2012;121(3):240–6. doi:10.1016/j.drugalcdep.2011.09.001.
47. Perkins KA, Giedgowd GE, Karelitz JL, Conklin CA, Lerman C. Smoking in response to negative mood in men versus women as a function of distress tolerance. *Nicotine Tob Res*. 2012;14(12):1418–25. doi:10.1093/ntr/nts075.
48. Piper ME, Cook JW, Schlam TR, Jorenby DE, Smith SS, Bolt DM, et al. Gender, race, and education differences in abstinence rates among participants in two randomized smoking cessation trials. *Nicotine Tob Res*. 2010;12(6):647–57. doi:10.1093/ntr/ntq067.
49. Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. *Nicotine Tob Res*. 2008;10(7):1245–50. doi:10.1080/14622200802097506.
50. Schnoll RA, Patterson F, Lerman C. Treating tobacco dependence in women. *J Womens Health (Larchmt)*. 2007;16(8):1211–8.
51. Xu J, Azizian A, Monterosso J, Domier CP, Brody AL, Fong TW, et al. Gender effects on mood and cigarette craving during early abstinence and resumption of smoking. *Nicotine Tob Res*. 2008;10(11):1653–61. doi:10.1080/14622200802412929. Erratum in: *Nicotine Tob Res*. 2009 Jan;11(1):106.
52. Hogle JM, Curtin JJ. Sex differences in negative affective response during nicotine withdrawal. *Psychophysiology*. 2006;43(4):344–56.
53. O'Dell LE, Torres OV. A mechanistic hypothesis of the factors that enhance vulnerability to nicotine use in females. *Neuropharmacology*. 2014;76(Pt B):566–80. doi:10.1016/j.neuropharm.2013.04.055. **This review proposes a hypothesis explaining how females experience greater rewarding effects of nicotine and more intense stress produced by withdrawal than males.**
54. Gentile NE, Andrekanic JD, Karwoski TE, Czambel RK, Rubin RT, Rhodes ME. Sexually dimorphic hypothalamic-pituitary-adrenal (HPA) responses to single-dose nicotine, continuous nicotine infusion, and nicotine withdrawal by mecamylamine in rats. *Brain Res Bull*. 2011;85(3–4):145–52. doi:10.1016/j.brainresbull.2011.03.001.
55. Skwara AJ, Karwoski TE, Czambel RK, Rubin RT, Rhodes ME. Influence of environmental enrichment on hypothalamic-pituitary-adrenal (HPA) responses to single-dose nicotine, continuous nicotine by osmotic mini-pumps, and nicotine withdrawal by mecamylamine in male and female rats. *Behav Brain Res*. 2012;234(1):1–10. doi:10.1016/j.bbr.2012.06.003.
56. Torres OV, Gentil LG, Natividad LA, Carcoba LM, O'Dell LE. Behavioral, biochemical, and molecular indices of stress are enhanced in female versus male rats experiencing nicotine withdrawal. *Front Psychiatry*. 2013;4:38. doi:10.3389/fpsy.2013.00038.
57. Torres OV, Pipkin JA, Ferree P, Carcoba LM, O'Dell LE. Nicotine withdrawal increases stress-associated genes in the nucleus accumbens of female rats in a hormone-dependent manner. *Nicotine Tob Res*. 2015;17(4):422–30. doi:10.1093/ntr/ntu278.
58. Scaramuzza A, De Palma A, Mameli C, Spiri D, Santoro L, Zuccotti GV. Adolescents with type 1 diabetes and risky behaviour. *Acta Paediatr*. 2010;99(8):1237–41. doi:10.1111/j.1651-2227.2010.01813.x.
59. Bishop FK, Maahs DM, Snell-Bergeon JK, Ogden LG, Kinney GL, Rewers M. Lifestyle risk factors for atherosclerosis in adults with type 1 diabetes. *Diab Vasc Dis Res*. 2009;6(4):269–75. doi:10.1177/1479164109346359.
60. Fan AZ, Rock V, Zhang X, Li Y, Elam-Evans L, Balluz L. Trends in cigarette smoking rates and quit attempts among adults with and without diagnosed diabetes, United States, 2001–2010. *Prev Chronic Dis*. 2013;10, E160. doi:10.5888/pcd10.120259.
61. de Artiñano A, Castro M. Experimental rat models to study the metabolic syndrome. *Br J Nutr*. 2009;102(9):1246–53. doi:10.1017/S0007114509990729.
62. O'Dell LE, Natividad LA, Pipkin JA, Roman F, Torres I, Jurado J, et al. Enhanced nicotine self-administration and suppressed dopaminergic systems in a rat model of diabetes. *Addict Biol*. 2014;19(6):1006–19. doi:10.1111/adb.12074.
63. Richardson JR, Pipkin JA, O'Dell LE, Nazarian A. Insulin resistant rats display enhanced rewarding effects of nicotine. *Drug Alcohol Depend*. 2014;140:205–7. doi:10.1016/j.drugalcdep.2014.03.028.
64. Blendy JA, Strasser A, Walters CL, Perkins KA, Patterson F, Berkowitz R, et al. Reduced nicotine reward in obesity: cross-comparison in human and mouse. *Psychopharmacol (Berl)*. 2005;180(2):306–15.

65. Eliasson B, Smith U, Lönnroth P. No acute effects of smoking and nicotine nasal spray on lipolysis measured by subcutaneous microdialysis. *Eur J Clin Invest*. 1997;27(6):503–9.
66. Haire-Joshu D, Heady S, Thomas L, Schechtman K, Fisher Jr EB. Depressive symptomatology and smoking among persons with diabetes. *Res Nurs Health*. 1994;17(4):273–82.
67. Spangler JG, Michielutte R, Bell RA, Knick S, Dignan MB, Summerson JH. Dual tobacco use among Native American adults in southeastern North Carolina. *Prev Med*. 2001;32(6):521–8.
68. Lydon DM, Wilson SJ, Child A, Geier CF. Adolescent brain maturation and smoking: what we know and where we're headed. *Neurosci Biobehav Rev*. 2014;45:323–42. doi:10.1016/j.neubiorev.2014.07.003.
69. O'Dell LE. A psychobiological framework of the substrates that mediate nicotine use during adolescence. *Neuropharmacology*. 2009;56 Suppl 1:263–78. doi:10.1016/j.neuropharm.2008.07.039.
70. O'Dell LE. NICO-TEEN: neural substrates that mediate adolescent tobacco abuse. *Neuropsychopharmacology*. 2011;36(1):356–7. doi:10.1038/npp.2010.138.
71. Tyas SL, Pederson LL. Psychosocial factors related to adolescent smoking: a critical review of the literature. *Tob Control*. 1998;7(4):409–20. Review.
72. Carroll ME, Anker JJ. Sex differences and ovarian hormones in animal models of drug dependence. *Horm Behav*. 2010;58(1):44–56. doi:10.1016/j.yhbeh.2009.10.001.
73. Becker JB, Perry AN, Westenbroek C. Sex differences in the neural mechanisms mediating addiction: a new synthesis and hypothesis. *Biol Sex Differ*. 2012;3(1):14. doi:10.1186/2042-6410-3-14.
74. Eliasson B. Cigarette smoking and diabetes. *Prog Cardiovasc Dis*. 2003;45(5):405–13.
75. O'Dell LE, Nazarian A. Enhanced vulnerability to tobacco use in persons with diabetes: a behavioral and neurobiological framework. *Prog Neuropsychopharmacol Biol Psychiatry*. 2015. doi:10.1016/j.pnpbp.2015.06.005.
76. Tonstad S. Practical implementation of varenicline as an aid to smoking cessation in clinical practice. *Pneumologia*. 2009;58(3):167–74.
77. Koob GF, Volkow ND. Neurocircuitry of addiction. *Neuropsychopharmacology*. 2010;35(1):217–38. doi:10.1038/npp.2009.110. Erratum in: *Neuropsychopharmacology*. 2010 Mar;35(4):1051.
78. Balfour DJ. Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. *Curr Drug Targets CNS Neurol Disord*. 2002;1(4):413–21.
79. Mansvelder HD, De Rover M, McGehee DS, Brussaard AB. Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. *Eur J Pharmacol*. 2003;480(1–3):117–23.
80. Hildebrand BE, Nomikos GG, Hertel P, Schilström B, Svensson TH. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. *Brain Res*. 1998;779(1–2):214–25.
81. Rada P, Jensen K, Hoebel BG. Effects of nicotine and mecamylamine-induced withdrawal on extracellular dopamine and acetylcholine in the rat nucleus accumbens. *Psychopharmacol (Berl)*. 2001;157(1):105–10.
82. Zhang L, Dong Y, Doyon WM, Dani JA. Withdrawal from chronic nicotine exposure alters dopamine signaling dynamics in the nucleus accumbens. *Biol Psychiatry*. 2012;71(3):184–91. doi:10.1016/j.biopsych.2011.07.024.
83. Natividad LA, Buczynski MW, Parsons LH, Torres OV, O'Dell LE. Adolescent rats are resistant to adaptations in excitatory and inhibitory mechanisms that modulate mesolimbic dopamine during nicotine withdrawal. *J Neurochem*. 2012;123(4):578–88. doi:10.1111/j.1471-4159.2012.07926.x.
84. Tejeda HA, Natividad LA, Orfila JE, Torres OV, O'Dell LE. Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner. *Psychopharmacol (Berl)*. 2012;224(2):289–301. doi:10.1007/s00213-012-2752-7.
85. Carcoba LM, Orfila JE, Natividad LA, Torres OV, Pipkin JA, Ferree PL, et al. Cholinergic transmission during nicotine withdrawal is influenced by age and pre-exposure to nicotine: implications for teenage smoking. *Dev Neurosci*. 2014;36(3–4):347–55. doi:10.1159/000360133.
86. Lemos JC, Wanat MJ, Smith JS, Reyes BA, Hollon NG, Van Bockstaele EJ, et al. Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive. *Nature*. 2012;490(7420):402–6. doi:10.1038/nature11436.
87. Beckstead MJ, Gantz SC, Ford CP, Stenzel-Poore MP, Phillips PE, Mark GP, et al. CRF enhancement of GIRK channel-mediated transmission in dopamine neurons. *Neuropsychopharmacology*. 2009;34(8):1926–35. doi:10.1038/npp.2009.25.
88. Bangasser DA, Curtis A, Reyes BA, Bethea TT, Parastatidis I, Ischropoulos H, et al. Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology. *Mol Psychiatry*. 2010;15(9):877. doi:10.1038/mp.2010.66. 896–904.
89. Valentino RJ, Van Bockstaele E, Bangasser D. Sex-specific cell signaling: the corticotropin-releasing factor receptor model. *Trends Pharmacol Sci*. 2013;34(8):437–44. doi:10.1016/j.tips.2013.06.004.
90. Lim DK, Lee KM, Ho IK. Changes in the central dopaminergic systems in the streptozotocin-induced diabetic rats. *Arch Pharm Res*. 1994;17(6):398–404.
91. Murzi E, Contreras Q, Teneud L, Valecillos B, Parada MA, De Parada MP, et al. Diabetes decreases limbic extracellular dopamine in rats. *Neurosci Lett*. 1996;202(3):141–4.
92. Owens WA, Sevak RJ, Galici R, Chang X, Javors MA, Galli A, et al. Deficits in dopamine clearance and locomotion in hypoinsulinemic rats unmask novel modulation of dopamine transporters by amphetamine. *J Neurochem*. 2005;94(5):1402–10.
93. Saller CF. Dopaminergic activity is reduced in diabetic rats. *Neurosci Lett*. 1984;49(3):301–6.
94. Williams JM, Owens WA, Turner GH, Saunders C, Dipace C, Blakely RD, et al. Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. *PLoS Biol*. 2007;5(10), e274.
95. Baldwin PR, Alanis R, Salas R. The role of the habenula in nicotine addiction. *J Addict Res Ther*. 2011 Oct 20;S1(2). **A theoretical paper that addresses how certain drugs that alter neuronal activity in the habenula may be effective therapies against tobacco use and drug addiction.**
96. Frahm S, Slimak MA, Ferrarese L, Santos-Torres J, Antolin-Fontes B, Auer S, et al. Aversion to nicotine is regulated by the balanced activity of $\beta 4$ and $\alpha 5$ nicotinic receptor subunits in the medial habenula. *Neuron*. 2011;70(3):522–35. doi:10.1016/j.neuron.2011.04.013.
97. Salas R, Sturm R, Boulter J, De Biasi M. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. *J Neurosci*. 2009;29(10):3014–8. doi:10.1523/JNEUROSCI.4934-08.2009.
98. Zhao-Shea R, DeGroot SR, Liu L, Vallaster M, Pang X, Su Q, Gao G, Rando OJ, Martin GE, George O, Gardner PD, Tapper AR. Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal. *Nat Commun*. 2015 Apr 21;6:6770. doi: 10.1038/ncomms7770. Erratum in: *Nat Commun*. 2015;6:7625. **This study identified a meso-interpeduncular circuit as**

- a potential source of CRF that may play an important role in modulating anxiety produced by nicotine withdrawal.**
- 99.♦♦ Dani JA, De Biasi M. Mesolimbic dopamine and habenulo-interpeduncular pathways in nicotine withdrawal. *Cold Spring Harb Perspect Med.* 2013 Jun 1;3(6). pii: a012138. doi: 10.1101/cshperspect.a012138. **A detailed overview of the habenula-interpeduncular (Hb-IPN) pathway as an important circuit that plays a critical role in modulating the behavioral effects of nicotine and withdrawal from this drug.**
 100. Jackson KJ, Martin BR, Changeux JP, Damaj MI. Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. *J Pharmacol Exp Ther.* 2008;325(1):302–12. doi:10.1124/jpet.107.132977.
 101. Jackson KJ, McIntosh JM, Brunsell DH, Sanjakdar SS, Damaj MI. The role of alpha6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal. *J Pharmacol Exp Ther.* 2009;331(2):547–54. doi:10.1124/jpet.109.155457.
 102. Modianos DT, Hitt JC, Flexman J. Habenular lesions produce decrements in feminine, but not masculine, sexual behavior in rats. *Behav Biol.* 1974;10(1):75–87.
 103. Simerly RB, Chang C, Muramatsu M, Swanson LW. Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: an in situ hybridization study. *J Comp Neurol.* 1990;294(1):76–95.
 - 104.♦ Antolin-Fontes B, Ables JL, Görlich A, Ibañez-Tallon I. The habenulo-interpeduncular pathway in nicotine aversion and withdrawal. *Neuropharmacology.* 2015;96(Pt B):213–22. doi:10.1016/j.neuropharm.2014.11.019. **This review describes the anatomical and functional connections of the MHB-IPN pathway and the contribution of specific nAChRs subtypes in this pathway in modulating nicotine-induced behavioral effects.**